Ryo Hanajiri1, Gelina M Sani1, Patrick J Hanley2, Cassia G Silveira3, Esper G Kallas3, Michael D Keller4, Catherine M Bollard5. 1. Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA. 2. Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA; The George Washington University, Washington, DC, USA. 3. Department of Infectious and Parasitic Diseases, School of Medicine, University of São Paulo, São Paulo, Brazil. 4. Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA; The George Washington University, Washington, DC, USA; Division of Allergy and Immunology, Children's National Health System, Washington, DC, USA. 5. Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA; The George Washington University, Washington, DC, USA; Division of Blood and Marrow Transplantation, Children's National Health System, Washington, DC, USA. Electronic address: cbollard@childrensnational.org.
Abstract
BACKGROUND: Zika virus (ZIKV) infection can cause severe birth defects in newborns with no effective currently available treatment. Adoptive transfer of virus-specific T cells has proven to be safe and effective for the prevention or treatment of many viral infections, and could represent a novel treatment approach for patients with ZIKV infection. However, extending this strategy to the ZIKV setting has been hampered by limited data on immunogenic T-cell antigens within ZIKV. Hence, we have generated ZIKV-specific T cells and characterized the cellular immune responses against ZIKV antigens. METHODS: T-cell products were generated from peripheral blood of ZIKV-exposed donors, ZIKV-naive adult donors and umbilical cord blood by stimulation with pentadecamer (15mer) overlapping peptide libraries spanning four ZIKV polyproteins (C, M, E and NS1) using a Good Manufacturing Practice-compliant protocol. RESULTS: We successfully generated T cells targeting ZIKV antigens with clinically relevant numbers. The ex vivo-expanded T cells comprised both CD4+ and CD8+ T cells that were able to produce Th1-polarized effector cytokines and kill ZIKV-infected HLA-matched monocytes, confirming functionality of this unique T-cell product as a potential "off-the-shelf" therapeutic. Epitope mapping using peptide arrays identified several novel HLA class I and class II-restricted epitopes within NS1 antigen, which is essential for viral replication and immune evasion. DISCUSSION: Our findings demonstrate that it is feasible to generate potent ZIKV-specific T cells from a variety of cell sources including virus naïve donors for future clinical use in an "off-the-shelf" setting.
BACKGROUND:Zika virus (ZIKV) infection can cause severe birth defects in newborns with no effective currently available treatment. Adoptive transfer of virus-specific T cells has proven to be safe and effective for the prevention or treatment of many viral infections, and could represent a novel treatment approach for patients with ZIKV infection. However, extending this strategy to the ZIKV setting has been hampered by limited data on immunogenic T-cell antigens within ZIKV. Hence, we have generated ZIKV-specific T cells and characterized the cellular immune responses against ZIKV antigens. METHODS: T-cell products were generated from peripheral blood of ZIKV-exposed donors, ZIKV-naive adult donors and umbilical cord blood by stimulation with pentadecamer (15mer) overlapping peptide libraries spanning four ZIKV polyproteins (C, M, E and NS1) using a Good Manufacturing Practice-compliant protocol. RESULTS: We successfully generated T cells targeting ZIKV antigens with clinically relevant numbers. The ex vivo-expanded T cells comprised both CD4+ and CD8+ T cells that were able to produce Th1-polarized effector cytokines and kill ZIKV-infected HLA-matched monocytes, confirming functionality of this unique T-cell product as a potential "off-the-shelf" therapeutic. Epitope mapping using peptide arrays identified several novel HLA class I and class II-restricted epitopes within NS1 antigen, which is essential for viral replication and immune evasion. DISCUSSION: Our findings demonstrate that it is feasible to generate potent ZIKV-specific T cells from a variety of cell sources including virus naïve donors for future clinical use in an "off-the-shelf" setting.
Authors: Ann M Leen; G Doug Myers; Uluhan Sili; M Helen Huls; Heidi Weiss; Kathryn S Leung; George Carrum; Robert A Krance; Chung-Che Chang; Jeffrey J Molldrem; Adrian P Gee; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Catherine M Bollard Journal: Nat Med Date: 2006-09-24 Impact factor: 53.440
Authors: Minhtran Charlotte Ngo; Jun Ando; Ann M Leen; Sravya Ennamuri; Natalia Lapteva; Juan F Vera; Amelia Min-Venditti; Martha P Mims; Helen E Heslop; Catherine M Bollard; Stephen Gottschalk; Cliona M Rooney Journal: J Immunother Date: 2014-05 Impact factor: 4.456
Authors: Patrick J Hanley; Conrad Russell Young Cruz; Barbara Savoldo; Ann M Leen; Maja Stanojevic; Mariam Khalil; William Decker; Jeffrey J Molldrem; Hao Liu; Adrian P Gee; Cliona M Rooney; Helen E Heslop; Gianpietro Dotti; Malcolm K Brenner; Elizabeth J Shpall; Catherine M Bollard Journal: Blood Date: 2009-05-14 Impact factor: 22.113
Authors: Ann M Leen; Catherine M Bollard; Adam M Mendizabal; Elizabeth J Shpall; Paul Szabolcs; Joseph H Antin; Neena Kapoor; Sung-Yun Pai; Scott D Rowley; Partow Kebriaei; Bimalangshu R Dey; Bambi J Grilley; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop Journal: Blood Date: 2013-04-22 Impact factor: 22.113
Authors: G Weber; U Gerdemann; I Caruana; B Savoldo; N F Hensel; K R Rabin; E J Shpall; J J Melenhorst; A M Leen; A J Barrett; C M Bollard Journal: Leukemia Date: 2013-03-01 Impact factor: 11.528
Authors: Brian D Foy; Kevin C Kobylinski; Joy L Chilson Foy; Bradley J Blitvich; Amelia Travassos da Rosa; Andrew D Haddow; Robert S Lanciotti; Robert B Tesh Journal: Emerg Infect Dis Date: 2011-05 Impact factor: 6.883
Authors: Ulrike Gerdemann; Usha L Katari; Anastasia Papadopoulou; Jacqueline M Keirnan; John A Craddock; Hao Liu; Caridad A Martinez; Alana Kennedy-Nasser; Kathryn S Leung; Stephen M Gottschalk; Robert A Krance; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Ann M Leen Journal: Mol Ther Date: 2013-06-20 Impact factor: 11.454
Authors: Robert S Lanciotti; Olga L Kosoy; Janeen J Laven; Jason O Velez; Amy J Lambert; Alison J Johnson; Stephanie M Stanfield; Mark R Duffy Journal: Emerg Infect Dis Date: 2008-08 Impact factor: 6.883
Authors: Victoria L Campbell; LeAnn Nguyen; Elise Snoey; Christopher L McClurkan; Kerry J Laing; Lichun Dong; Alessandro Sette; Cecilia S Lindestam Arlehamn; Danny M Altmann; Rosemary J Boyton; Justin A Roby; Michael Gale; Mars Stone; Michael P Busch; Phillip J Norris; David M Koelle Journal: Immunohorizons Date: 2020-08-04
Authors: Maria Cancio; Rachele Ciccocioppo; Patricia R M Rocco; Bruce L Levine; Vincenzo Bronte; Catherine M Bollard; Daniel Weiss; Jaap Jan Boelens; Patrick J Hanley Journal: Cytotherapy Date: 2020-05-07 Impact factor: 5.414